Guangzhou Baiyunshan Pharmaceutical Announces Capital Increase for Subsidiary

Confident Investing Starts Here:

Guangzhou Baiyunshan Pharmaceutical Holdings Company ( (HK:0874) ) just unveiled an announcement.

Guangzhou Baiyunshan Pharmaceutical Holdings Company has announced a capital increase for its subsidiary, Baiyunshan Biological, with contributions from the company itself, GP Venture Capital Fund, and Guangzhou Time Honored Brand Fund. This move will raise Baiyunshan Biological’s registered capital significantly, though the company’s equity interest will remain unchanged. The transaction, classified as a connected transaction under Hong Kong Listing Rules, is exempt from independent shareholders’ approval but requires reporting and announcement compliance.

The most recent analyst rating on (HK:0874) stock is a Hold with a HK$25.40 price target. To see the full list of analyst forecasts on Guangzhou Baiyunshan Pharmaceutical Holdings Company stock, see the HK:0874 Stock Forecast page.

More about Guangzhou Baiyunshan Pharmaceutical Holdings Company

Guangzhou Baiyunshan Pharmaceutical Holdings Company operates in the pharmaceutical industry, focusing on the development and production of various pharmaceutical products. The company is known for its commitment to innovation and quality in the healthcare sector, serving a broad market with its diverse range of products.

Average Trading Volume: 1,401,444

Technical Sentiment Signal: Sell

Current Market Cap: HK$44.95B

For an in-depth examination of 0874 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks’

Best Online Brokers

, and find the ideal broker for your trades.

Report an Issue

No Byline Policy

Editorial Guidelines

Corrections Policy

Source